Ruxolitinib is recommended, within its marketing authorisation, as an option for treating acute graft versus host disease (GvHD) that has an inadequate response to corticosteroids in people 12 years ...

Approximately two-thirds of patients responded to teduglutide, which is sold under the brand name Gattex as a treatment for ...

Achieved $20.0 million in Revuforj net revenue in the first quarter of 2025, the first full quarter of the U.S. launch. Revuforj was launched in the U.S. in late November 2024 for the treatment of ...

A Phase 2 trial evaluating axatilimab (Niktimvo ™) in combination with ruxolitinib (Jakafi) in patients with newly diagnosed chronic GVHD is ongoing and enrolling patients. A Phase 3 trial ...

Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

The year-over-year increase was due to an increase in axatilimab-related costs primarily driven by the IPF trial, the frontline chronic GVHD trial with ruxolitinib being conducted in partnership ...

A Phase 2, open-label, randomized, multicenter trial of axatilimab in combination with ruxolitinib in patients ≥ 12 years of age with newly diagnosed chronic GVHD. A pivotal Phase 3, randomized ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Good day, everyone, and welcome to the Syndax First Quarter 2025 ...

The year-over-year increase was due to an increase in axatilimab-related costs primarily driven by the IPF trial, the frontline chronic GVHD trial with ruxolitinib being conducted in partnership ...